for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sol Gel Technologies Ltd

SLGL.OQ

Latest Trade

8.84USD

Change

0.23(+2.67%)

Volume

1,163

Today's Range

8.49

 - 

8.85

52 Week Range

5.61

 - 

11.17

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
8.61
Open
8.85
Volume
1,163
3M AVG Volume
0.49
Today's High
8.85
Today's Low
8.49
52 Week High
11.17
52 Week Low
5.61
Shares Out (MIL)
20.39
Market Cap (MIL)
181.24
Forward P/E
-8.10
Dividend (Yield %)
--

Latest Developments

More

Sol Gel Technologies Reports Qtrly Loss Per Share $0.26

Sol-Gel Announces Positive Top-Line Results From Epsolay Phase 3 Program In Papulopustular Rosacea

Sol-Gel Technologies Announces Seventh Agreement For Generic Product Candidates With Perrigo

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Sol Gel Technologies Ltd

Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.

Industry

Biotechnology & Drugs

Contact Info

Weizmann Science Park, 7, Golda Me'ir

+972.8.9313433

http://www.sol-gel.com

Executive Leadership

Alon Seri-Levy

Chief Executive Officer, Co-Founder, Director

Gilad Mamlok

Chief Financial Officer

Itzik Yosef

Vice President - Operations

Ofra Levy-Hacham

Vice President - Quality and Regulatory Affairs

Karine Neimann

Vice President - Projects and Planning, Chief Chemist

Key Stats

1.60 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2017

-5.020

2018

-1.800

2019(E)

-1.060
Price To Earnings (TTM)
--
Price To Sales (TTM)
12.78
Price To Book (MRQ)
3.08
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-43.67
Return on Equity (TTM)
-40.39

Latest News

BRIEF-Sol-Gel Technologies Reported Loss Of $5.7 Million For Q1

* SOL-GEL TECHNOLOGIES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Sol-Gel Technologies Reports Q4 Loss Of $5.5 Mln Vs. Loss Of $4.9 Mln A Year Earlier

* SOL-GEL TECHNOLOGIES REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Sol-Gel Technologies Announces Pricing Of IPO

* PRICING OF ITS INITIAL PUBLIC OFFERING OF 6.3 MILLION ORDINARY SHARES AT A PUBLIC OFFERING PRICE OF $12.00 PER ORDINARY SHARE Source text for Eikon: Further company coverage:

BRIEF-Sol Gel Technologies Sees IPO Of 5 Mln Ordinary Shares

* SOL GEL TECHNOLOGIES LTD SEES IPO OF 5.0 MILLION ORDINARY SHARES PRICED BETWEEN $11.00 AND $13.00 PER ORDINARY SHARE - SEC FILING

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up